Dr Lisa Rojkjaer, head of clinical development, MorphoSys
pharmafile | October 15, 2009 | Appointment | Research and Development | appointment, morphosys, research and development
MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development.
Dr Rojkjaer joins MorphoSys from Novartis where she most recently held the position of head of medical affairs – hematology, Europe.
Before that she was global clinical programme head for Exjade, where she was responsible for all clinical activities in Europe for Novartis’ haematology portfolio including Gleevec and Exjade.
Prior to Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, USA as the director of global medical affairs biopharmaceuticals and later director, clinical development haematology.
During her time with Novo Nordisk she established a global medical affairs group for biopharmaceuticals and headed the clinical development of the US haematology portfolio amongst other accomplishments.
Dr Rojkjaer is a board certified haematologist and received her medical degree from the University of Toronto, where she also did her residency in internal medicine and fellowship in haematology.
She has held academic and hospital appointments in the US, Canada and Europe.
Related Content
Novartis to acquire MorphoSys AG for €2.7bn
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an …
FDA gives nod for Monjuvi combo for second-line relapsed or refractory diffuse large B-cell lymphoma
The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal …